In honor of Gilead‘s newly approved, and cheaper, hepatitis C drug we decided to show the biomarker, trial and company landscape for hepatitis C. You can read more about Gilead’s new drug here, here and here.
Purple: Company
Red: Trials
Blue: Biomarkers
Green: Disease
